Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin versus placebo injection into cardiac fat pad for prevention of in-hospital atrial fibrillation after open-heart surgery
IRCT20120215009014N350Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Botulinum toxin type A with Placebo (2 arms). Primary endpoints: Intra-hospital atrial fibrillation and Left ventricular ejection fraction. Started Jan 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20120215009014N350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N350.